R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Oncology A cancer treatment modality that prioritises QoL, with Ben Z... Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Oncology Engineering “smarter” cells, with Tim Lu Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone
R&D The secrets of the secretome, with Hans Keirstead Immunis CEO Hans Keirstead explains why his company thinks the immune system is key to tackling healthspan and longevity.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.